EUCTR2004-000919-26-FI进行中（未招募）1 期
Phase II, randomized, pharmokinetic, dose finding, and dose frequency determination using rt-PA in intraventricular hemorrhage - CLEAR IVH
ewcastle upon Tyne Hospitals NHS Trust0 个研究点目标入组 52 人开始时间: 2005年11月21日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Spontaneous intracerebral haemorrhage < 30cc, intraventricular haemorrhage (IVH), intraventricular catheter (IVC) placed as standard care, systolic BP>90 mmHg and <185 mmHg, diastolic BP <105 mmHg, pre ICH rankin of 0 or 1, age 18-75, clot size 6 hrs after IVC placement must be within 5cc of presenting clot size, able to receive first dose within 48 hours of CT scan diagnosing IVH, symptom onset to diagnostic CT , 12 hrs.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Suspected or untreated aneurysm or arteriovenous malformation, clotting disorders, platelet count < 100,000, INR > 1.7, PT > 15s, elevated APTT, ICH enlargement in 6 hours after placement of intraventricular catheter, internal or surface bleeding, any other condition that would pose a significant hazard to the subject if investigational therapy were initiated
研究者
相似试验
进行中（未招募）
1 期
Phase II, randomized, pharmokinetic, dose finding, and dose frequency determination using rt-PA in intraventricular hemorrhage - CLEAR IVHIntracerebral haemorrhage with intraventricular extensionEUCTR2004-000919-26-GBewcastle upon Tyne Hospitals NHS Trust52
进行中（未招募）
1 期
A study to find and confirm the dose and assess the safety, reactogenicity and immune response of a vaccine against influenza in healthy younger and older adultsCTIS2022-502308-66-00GlaxoSmithKline Biologicals1,272
进行中（未招募）
不适用
A Phase II, open-label, randomised, dose-finding study to compare the efficacy (in terms of clearance of RhD-positive RBCs) and safety of LFB-R593, a monoclonal anti-RhD antibody, vs Rhophylac®, a polyclonal anti-RhD immunoglobulin in healthy RhD negative volunteersProphyllaxis against RhD isoimmunisation during pregnancy (anti-D prophylaxis)Treatment of RhD negative individuals after incompatible transfusions with blood components containing RhD-positive red blood cells.MedDRA version: 9.1Level: LLTClassification code 10019513Term: Hemolytic disease of fetus or newborn, due to isoimmunizationMedDRA version: 9.1Level: LLTClassification code 10044360Term: Transfusion with incompatible bloodEUCTR2009-011017-24-DEFB Biotechnologies
尚未招募
2 期
Phase IIa Clinical Trial for Dose-Finding, Pharmacokinetics, Safety, Immunomodulatory Activity, and Inhibitory Activity on Cancer Progression of Capsule Formulation of the Standardized Extarct of Atractylodes lancea in Patients with Unresectable or Metastatic Liver Tumorlate-stage cholangiocarcinomacholangiocarcinoma,Atractylodes lanceastandardized extractphase IIa clinical trialTCTR20210129007ational Research Council of Thailand (NRCT)90
进行中（未招募）
1 期
Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative ColitisModerate to Severe Active Ulcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2021-002537-41-DEAmgen Inc.320